ArticleBlood2018
Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines.
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 59 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Proton beam therapy indications in the Kingdom of Saudi Arabia: A SARO clinical practice guideline.Saudi medical journal · 2025Guideline
- Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma-A Regression Analysis of Dose-Response.Hematological oncology · 2025Pooled it
- Radiation exposure of breast tissue in lymphoma radiotherapy: a systematic review of breast dose metrics published since 2000.Acta oncologica (Stockholm, Sweden) · 2025Pooled it
- ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic.Blood · 2020Guideline
- Review
- Clinical implementation of intensity modulated proton therapy in breath-hold for mediastinal lymphoma patients using surface monitoring and nasal high-flow therapy.Physics and imaging in radiation oncology · 2026Article
- Improved organs-of-interest dose reduction potential with intensity modulated proton therapy and breath-hold in mediastinal lymphoma.Physics and imaging in radiation oncology · 2026Article
- Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma.International journal of particle therapy · 2026Article
- Clinical advances and challenges in dose constraints for organs at risk in proton therapy: A systematic review of the last decade's literature.Precision radiation oncology · 2025Review
- Towards proton therapy guidelines for radiation therapists and dosimetrists: A scoping review.Technical innovations & patient support in radiation oncology · 2025Review
- Radiotherapy alone with curative intent in a case of limited-stage extranodal NK/T-cell lymphoma nasal type: a case report and review of the literature.Annals of hematology · 2025Review
- Cardioprotection for radiation-induced heart disease in breast cancer patients.Frontiers in pharmacology · 2025Review
- Article
- Minimally Invasive Sampling of Mediastinal Lesions.Life (Basel, Switzerland) · 2024Review
- Proton Therapy Reduces the Effective Dose to Immune Cells in Mediastinal Hodgkin Lymphoma Patients.International journal of particle therapy · 2024Article
- Article
- Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy.Blood advances · 2024Article
- Pencil beam scanning proton therapy for mediastinal lymphomas in deep inspiration breath-hold: a retrospective assessment of plan robustness.Acta oncologica (Stockholm, Sweden) · 2024Article
- Evolution of radiotherapy techniques for mediastinal Hodgkin lymphoma: a single-center experience.Mediastinum (Hong Kong, China) · 2024Article
- Radiotherapy dose de-escalation in patients with high grade non-Hodgkin lymphoma in a real-world clinical practice.Radiation oncology journal · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among adult lymphoma survivors, radiation treatment techniques that increase the excess radiation dose to organs at risk (OARs) put patients at risk for increased side effects, especially late toxicities. Minimizing radiation to OARs in adults patients with Hodgkin and non-Hodgkin lymphomas involving the mediastinum is the deciding factor for the choice of treatment modality. Proton therapy may help to reduce the radiation dose to the OARs and reduce toxicities, especially the risks for cardiac morbidity and second cancers. Because proton therapy may have some disadvantages, identifying the patients and the circumstances that may benefit the most from proton therapy is important. We present modern guidelines to identify adult lymphoma patients who may derive the greatest benefit from proton therapy, along with an analysis of the advantages and disadvantages of proton treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.